Drugs

, Volume 70, Issue 18, pp 2357–2372 | Cite as

Adverse Effects and Tolerability of Medications for the Treatment of Tobacco Use and Dependence

Review Article

Abstract

Tobacco use is the leading cause of preventable death and disability in the world. Although gradually declining in most developed countries, the prevalence of tobacco use has increased among developing countries. Treatment for tobacco use and dependence is effective, although long-term abstinence rates remain disappointingly low. In response, new treatments continue to be developed. In addition, many of the pharmacotherapies that have been available for years have found new applications with the use of medication combinations, higher doses and a longer duration of therapy for approved medications.

There are now seven medications (nicotine patch, nicotine gum, nicotine lozenge, nicotine inhaler, nicotine nasal spray, bupropion sustained release and varenicline) approved for tobacco dependence treatment in most countries, and many national and professional society practice guidelines recommend their use. Although each of the medications used for tobacco dependence treatment has been rigorously tested for efficacy and safety, broader experience in clinical trials and in observational population-based studies suggests that adverse events associated with these medications are relatively common. Since 2008, two of the medications (varenicline and bupropion) have come under increasing scrutiny because of reports of unexplained serious adverse events (SAEs), including behaviour change, depression, self-injurious thoughts and suicidal behaviour. To date, this association has not been shown to be caused by these medications, but concerns about medication safety continue. Prescribers require a working knowledge of the common adverse effects for all of these medications as well as a more detailed knowledge of the SAE potential.

Nicotine replacement therapy (NRT) has been rigorously tested in clinical trials for over 30 years. A number of adverse effects are commonly associated with NRT use, although SAEs are rare. The adverse effects associated with NRT are due to the pharmacological action of nicotine as well as the mode and site of the NRT application. Bupropion has been tested in over 40 controlled clinical trials and has been associated with higher rates of treatment discontinuation due to adverse events than NRTs. A number of SAEs are associated with bupropion and new warnings were recently added to bupropion prescribing information because of observed neuropsychiatric symptoms including suicidal thoughts and behaviours. Varenicline is the most recently approved medication for tobacco dependence treatment and, although proven safe in clinical testing, new safety concerns have arisen based on postmarketing reports. Warnings have been added to the prescribing information for varenicline because of neuropsychiatric symptoms also including suicidal thoughts and behaviours.

Informed decision making regarding the use of pharmacotherapy for the treatment of tobacco dependence requires knowledge about the risks of drug treatment that is weighed against the risks of continued tobacco use and the benefits of treatment. Over half of all long-term smokers will die of a tobaccorelated disease and the risk of a serious or life-threatening adverse event with tobacco cessation pharmacotherapy is vanishingly small. Pharmacotherapy for tobacco dependence is also among the most cost-effective preventive health interventions. Given these factors, the benefit: risk ratio is strongly in favour of pharmacotherapy for tobacco dependence treatment in virtually all smokers who are motivated to quit.

Notes

Acknowledgments

No funding was provided for the preparation of this review. The review represents the work of the authors, who had sole control over the collection of data, interpretation of data, preparation and approval of the manuscript. The authors have no relevant financial interests or other conflicts of interest to declare with regard to the contents of this review. All authors made substantial contributions to the preparation, review and final approval of the manuscript and meet criteria for authorship.

References

  1. 1.
    Shafey O, Eriksen M, Ross H, et al. The tobacco atlas. 3rd ed. Atlanta (GA): American Cancer Society, 2009Google Scholar
  2. 2.
    Mokdad AH, Marks JS, Stroup DF, et al. Actual causes of death in the United States, 2000. JAMA 2004; 291: 1238–45PubMedCrossRefGoogle Scholar
  3. 3.
    Centers for Disease Control and Prevention (CDC). Annual smoking-attributable mortality, years of potential life lost, and economic costs: United States, 1995–1999. MMWR Morb Mortal Wkly Rep 2002; 51(14): 300–3Google Scholar
  4. 4.
    Cancer facts and figures 2007. American Cancer Society, 2007 [online]. Available from URL: http://www.cancer.org [Accessed 2010 Feb 3]
  5. 5.
    CDC. National health interview survey [online]. Available from URL: http://www.cdc.gov/nchs/data/nhis/earlyrelease/200912_08.pdf [Accessed 2010 Feb 11]
  6. 6.
    Fiore MC, Jaén CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Clinical practice guideline. Rockville (MD): U.S. Department of Health and Human Services, Public Health Service, 2008 MayGoogle Scholar
  7. 7.
    Schroeder SA. What to do with a patient who smokes. JAMA 2005 Jul 27; 294(4): 482–7PubMedCrossRefGoogle Scholar
  8. 8.
    Lancaster T, Hajek P, Stead LF, et al. Prevention of relapse after quitting smoking: a systematic review of trials. Arch Intern Med 2006 Apr 24; 166(8): 828–35PubMedCrossRefGoogle Scholar
  9. 9.
    Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008 Jan 23; (1): CD000146Google Scholar
  10. 10.
    Food and Drug Administration. Postmarket drug safety information for patients and providers. Information for healthcare professionals: varenicline (marketed as Chantix) and bupropion (marketed as Zyban, Wellbutrin, and generics) [online]. Available from URL: http://www.fda.gov/ Drugs/DrugSafety/PostmarketDrugSafetyInformationfor PatientsandProviders/DrugSafetyInformationforHeathcare Professionals/ucm169986.htm [Accessed 2010 Sep 24]Google Scholar
  11. 11.
    Food and Drug Administration. Public health advisory: important information on Chantix (varenicline) [online]. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInfor mationforHeathcareProfessionals/PublicHealthAdvisories/ucm051136.htm [Accessed 2010 Sep 24]
  12. 12.
    Raw M, Regan S, Rigotti NA, et al. A survey of tobacco dependence treatment guidelines in 31 countries. Addiction 2009; 104: 1243–50PubMedCrossRefGoogle Scholar
  13. 13.
    Zwar N, Richmond R, Borland R, et al. Smoking cessation pharmacotherapy: an update for health professionals. Melbourne (VIC): Royal Australian College of General Practitioners, 2007Google Scholar
  14. 14.
    West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. Thorax 2000; 55: 987–99PubMedCrossRefGoogle Scholar
  15. 15.
    Eisenberg MJ, Filion KB, Yavin D, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ 2008; 179: 135–44PubMedGoogle Scholar
  16. 16.
    Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2007 Jan 24; (1): CD006103Google Scholar
  17. 17.
    DiMatteo MR. Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004; 42: 200–9PubMedCrossRefGoogle Scholar
  18. 18.
    Rohsenow DJ, Colby SM, Monti PM, et al. Predictors of compliance with naltrexone among alcoholics. Alcohol Clin Exp Res 2000; 24(10): 1542–9PubMedCrossRefGoogle Scholar
  19. 19.
    Burns EK, Levinson AH. Discontinuation of nicotine replacement therapy among smoking-cessation attempters. Am J Prev Med 2008; 34: 212–5PubMedCrossRefGoogle Scholar
  20. 20.
    Vogt F, Hall S, Marteau TM. Understanding why smokers do not want to use nicotine dependence medications to stop smoking: qualitative and quantitative studies. Nicotine Tob Res 2008; 10(8): 1405–13PubMedCrossRefGoogle Scholar
  21. 21.
    Mills EJ, Wu P, Lockhart I, et al. Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation: a systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals. Tob Induc Dis 2010; 8: 8PubMedCrossRefGoogle Scholar
  22. 22.
    Tonnesen P, Paoletti P, Gustavsson G, et al. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Eur Resp J 1999; 13: 238–46CrossRefGoogle Scholar
  23. 23.
    Ossip DJ, Abrams SM, Mahoney MC, et al. Adverse effects of nicotine replacement therapy among quitline clients. Nicotine Tob Res 2009; 11: 408–17PubMedCrossRefGoogle Scholar
  24. 24.
    Diagnostic and statistical manual of mental disorders, DSM-IV. 4th ed. Washington, DC: American Psychiatric Association, 1994Google Scholar
  25. 25.
    Oncken C, Cooney J, Feinn R, et al. Transdermal nicotine for smoking cessation in postmenopausal women. Addict Behav 2007; 32: 296–309PubMedCrossRefGoogle Scholar
  26. 26.
    Hughes JR, Lesmes GR, Hatsukami DK, et al. Are higher doses of nicotine replacement more effective for smoking cessation? Nicotine Tob Res 1999; 1: 169–74PubMedCrossRefGoogle Scholar
  27. 27.
    Shiffman S, Dresler CM, Hajek P, et al. Efficacy of a nicotine lozenge for smoking cessation. Arch Intern Med 2002; 162: 1267–76PubMedCrossRefGoogle Scholar
  28. 28.
    Schneider NG, Olmstead R, Mody FV, et al. Efficacy of a nicotine nasal spray in smoking cessation: a placebocontrolled, double-blind trial. Addiction 1995; 90: 1671–82PubMedCrossRefGoogle Scholar
  29. 29.
    Sutherland G, Stapleton JA, Russell MAH, et al. Randomised controlled trial of nasal nicotine spray in smoking cessation. Lancet 1992; 340: 324–9PubMedCrossRefGoogle Scholar
  30. 30.
    Hjalmarson AI, Franzon M, Westin A, et al. Effect of nicotine nasal spray on smoking cessation: a randomized, placebo-controlled, double-blind study. Arch Intern Med 1994; 154: 2567–72PubMedCrossRefGoogle Scholar
  31. 31.
    Blondal T, Franzon M, Westin A. A double-blind randomized trial of nicotine nasal spray as an aid in smoking cessation. Eur Resp J 1997; 10: 1585–90CrossRefGoogle Scholar
  32. 32.
    Joseph AM, Norman SM, Ferry LH, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 1996; 335: 1792–8PubMedCrossRefGoogle Scholar
  33. 33.
    Joseph AM, Fu SS. Safety issues in pharmacotherapy for smoking cessation in patients with cardiovascular disease. Prog Cardiovasc Dis 2003; 45: 429–41PubMedCrossRefGoogle Scholar
  34. 34.
    Areechon W, Punnotok J. Smoking cessation through the use of nicotine chewing gum: a double-blind trial in Thailand. Clin Ther 1988; 10(2): 183–6PubMedGoogle Scholar
  35. 35.
    Fortmann SP, Killen JD, Telch MJ, et al. Minimal contact treatment for smoking cessation: a placebo controlled trial of nicotine polacrilex and self-directed relapse prevention: initial results of the Stanford Stop Smoking Project. JAMA 1988 Sep 16; 260(11): 1575–80PubMedCrossRefGoogle Scholar
  36. 36.
    Harackiewicz JM, Blair LW, Sansone C, et al. Nicotine gum and self-help manuals in smoking cessation: an evaluation in a medical context. Addict Behav 1988; 13(4): 319–30PubMedCrossRefGoogle Scholar
  37. 37.
    Schneider NG, Olmstead R, Nilsson F, et al. Efficacy of a nicotine inhaler in smoking cessation: a double-blind, placebocontrolled trial. Addiction 1996 Sep; 91(9): 1293–306PubMedCrossRefGoogle Scholar
  38. 38.
    Glover ED, Glover PN, Franzon M, et al. A comparison of a nicotine sublingual tablet and placebo for smoking cessation. Nicotine Tob Res 2002 Nov; 4(4): 441–50PubMedCrossRefGoogle Scholar
  39. 39.
    Shiffman S, Fergusin SG, Strahs KR. Quitting by smoking reduction using nicotine gum: a randomized controlled trial. Am J Prev Med 2009; 36: 96–104PubMedCrossRefGoogle Scholar
  40. 40.
    McRobbie H, Hajek P, Gillison F. The relationship between smoking cessation and mouth ulcers. Nicotine Tob Res 2004 Aug; 6(4): 655–9PubMedCrossRefGoogle Scholar
  41. 41.
    Lunell E, Molander L, Ekberg K, et al. Site of nicotine absorption from a vapour inhaler: comparison with cigarette smoking. Eur J Clin Pharmacol 2000; 55: 737–41PubMedCrossRefGoogle Scholar
  42. 42.
    Hjalmarson A, Nilsson F, Sjostrom L, et al. The nicotine inhaler in smoking cessation. Arch Intern Med 1997; 157: 1721–8PubMedCrossRefGoogle Scholar
  43. 43.
    Leischow SJ, Nilsson F, Franzon M, et al. Efficacy of the nicotine inhaler as an adjunct to smoking cessation. Am J Health Behav 1996; 20: 364–71Google Scholar
  44. 44.
    Tonnesen P, Norregaard J, Mikkelsen K, et al. A double-blind trial of a nicotine inhaler for smoking cessation. JAMA 1993; 269: 1268–71PubMedCrossRefGoogle Scholar
  45. 45.
    Bende M, Burian P, Danielsson G P, et al. Evaluation of side effects after nicotine nasal spray in patients with chronic rhinitis. Rhinology 1998; 36: 98–100PubMedGoogle Scholar
  46. 46.
    Greenland S, Satterfield MH, Lanes SF. A meta-analysis to assess the incidence of adverse effects associated with the transdermal nicotine patch. Drug Saf 1998; 18: 297–308PubMedCrossRefGoogle Scholar
  47. 47.
    Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007 Jan 24; (1): CD000031Google Scholar
  48. 48.
    Johnston JA, Fiedler-Kelly J, Glover ED, et al. Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation. Nicotine Tob Res 2001; 3: 131–40PubMedCrossRefGoogle Scholar
  49. 49.
    Hsyu PH, Singh A, Giargiari TD, et al. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol 1997; 37: 737–43PubMedGoogle Scholar
  50. 50.
    Davidson J. Seizures and bupropion: a review. J Clin Psychiatry 1989; 50: 256–61PubMedGoogle Scholar
  51. 51.
    Johnston JA, Lineberry CG, Ascher JA, et al. A 102-center prospective study of seizure in association with bupropion. J Clin Psychiatry 1991; 52: 450–6PubMedGoogle Scholar
  52. 52.
    Medicines Control Agency. Zyban safety update (080402. doc). London: Medicines Control Agency, Executive Agency of the Department of Health, 2002 Apr 11Google Scholar
  53. 53.
    Peloso PM. Serum sickness-like reaction with bupropion [letter]. JAMA 1999; 282: 1817PubMedCrossRefGoogle Scholar
  54. 54.
    Lineberry TW, Peters Jr GE, Bostwick JM. Bupropioninduced erythema multiforme. Mayo Clin Proc 2001; 76: 664–6PubMedGoogle Scholar
  55. 55.
    US Food and Drug Administration. The smoking cessation aids varenicline (marketed as Chantix) and bupropion (marketed as Zyban and generics): suicidal ideation and behavior. FDA Safety Newsletter 2009; 2(1): 1–4Google Scholar
  56. 56.
    Boshier A, Wilton LV, Shakir SAW. Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000. Eur J Clin Pharmacol 2003; 59: 767–73PubMedCrossRefGoogle Scholar
  57. 57.
    Hubbard R, Lewis S, West J, et al. Bupropion and the risk of sudden death: a self-controlled case-series analysis using The Health Improvement Network. Thorax 2005; 60: 848–50PubMedCrossRefGoogle Scholar
  58. 58.
    Dobson R. Antismoking drug comes under scrutiny after deaths. BMJ 2001; 322: 452PubMedCrossRefGoogle Scholar
  59. 59.
    Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo-and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006; 166: 1561–8PubMedCrossRefGoogle Scholar
  60. 60.
    Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006; 166: 1571–7PubMedCrossRefGoogle Scholar
  61. 61.
    Niaura R, Hays JT, Jorenby DE, et al. The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial. Curr Med Res Op 2008; 24: 1931–41CrossRefGoogle Scholar
  62. 62.
    Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296: 47–55PubMedCrossRefGoogle Scholar
  63. 63.
    Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296: 56–63PubMedCrossRefGoogle Scholar
  64. 64.
    Tonstad S, Tonnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006; 296: 64–71PubMedCrossRefGoogle Scholar
  65. 65.
    Rigotti NA, Pipe AL, Benowitz NL, et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 2010; 121: 221–9PubMedCrossRefGoogle Scholar
  66. 66.
    Tashkin DP, Rennard S, Hays JT, et al. Effects of varenicline on smoking cessation in mild-to-moderate COPD: a randomized controlled trial. Chest. Epub 2010 Sep 23Google Scholar
  67. 67.
    Aubin HJ, Boback A, Britton JR, et al. Varenicline versus transdermal nicotine for smoking cessation: results from a randomized, open-label trial. Thorax 2008; 1: 1–8Google Scholar
  68. 68.
    Nakamura M, Oshima A, Fujimoto Y, et al. Efficacy and tolerability of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, in a 12-week randomized, placebocontrolled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther 2007; 29: 140–56CrossRefGoogle Scholar
  69. 69.
    Stapleton JA, Watson L, Spirling LI, et al. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction 2008; 103: 146–54PubMedCrossRefGoogle Scholar
  70. 70.
    Tsai ST, Cho HJ, Cheng HS, et al. A randomized, placebocontrolled trial of varenicline, a selective a4b2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther 2007; 29: 1027–39PubMedCrossRefGoogle Scholar
  71. 71.
    Gunnell D, Irvine D, Wise L, et al. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ 2009; 339: b3805PubMedCrossRefGoogle Scholar
  72. 72.
    Russ C, Davies S, Flammer M, et al. Incidence of psychiatric adverse effects other than depression in randomized, double-blind, placebo-controlled varenicline clinical trials [poster]. 10th Annual Conference of the Society for Research on Nicotine and Tobacco-Europe; 2008 Sep 23–26; RomeGoogle Scholar
  73. 73.
    Tonstad S, Davies S, Flammer M, et al. Incidence of depression in randomized, double-blind, placebo-controlled varenicline clinical trials [poster]. 10th Annual Conference of Society for Research on Nicotine and Tobacco-Europe; 2008 Sep 23–26; RomeGoogle Scholar
  74. 74.
    Doll R, Peto R, Boreham J, et al. Mortality in relation to smoking: 50 years’ observations on male British doctors. BMJ 2004 Jun; 328: 1519–33PubMedCrossRefGoogle Scholar
  75. 75.
    Kenfield SA, Stampfer MJ, Rosner BA, et al. Smoking and smoking cessation in relation to mortality in women. JAMA 2008; 299: 2037–47PubMedCrossRefGoogle Scholar
  76. 76.
    Reimherr FW, Cunningham LA, Batey SR et al. A multicenter evaluation of the efficacy and safety of 150 and 300mg/d sustained-release bupropion tablets versus placebo in depressed outpatients. Clin Ther 1998; 20: 505–16PubMedCrossRefGoogle Scholar
  77. 77.
    Evins AE, Mays VK, Rigotti NA, et al. A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. Nicotine Tob Res 2001; 3: 397–403PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  1. 1.Mayo Clinic Nicotine Dependence CenterMayo Clinic College of MedicineRochesterUSA

Personalised recommendations